Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
RESEARCH TOOLSreports
Holding AVTE?
Track your performance easily
AVTE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $32.42
Previous Close$1.9
Volume170.65K
Average Volume (3M)1.19M
Market Cap
$56.00M
Enterprise Value-$47.52M
Total Cash (Recent Filing)$104.20M
Total Debt (Recent Filing)$681.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 11, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding28,867,711
10 Day Avg. Volume231,742
30 Day Avg. Volume1,186,639
Standard Deviation0.32
R-Squared0.03
Alpha-0.00210
Financial Highlights & Ratios
Price to Book (P/B)0.62
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$2.25Price Target Upside18.42% Upside
Rating ConsensusHold
Number of Analyst Covering6
Aerovate Therapeutics News
Bulls Say, Bears Say
Bulls Say
Potential UpsideMeaningful upside potential should IMPAHCT demonstrate >20% improvements on the PVR endpoint and ~20m improvements on 6MWD with uneventful safety/tolerability.
Product PipelineThe company has a strong pipeline of new products slated for release.
Revenue StabilityThe company has shown resilience in maintaining a stable revenue stream.
Bears Say
Clinical TrialsAerovate is halting enrollment and shutting down the Ph3 study.
Product EffectivenessAV-101 did not separate from placebo on its primary endpoint in the Phase 2b portion of IMPAHCT.
Stock PerformanceShares are down -90% and are likely to stay depressed.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AVTE FAQ
What was Aerovate Therapeutics’s price range in the past 12 months?
Aerovate Therapeutics lowest stock price was $1.25 and its highest was $32.41 in the past 12 months.
What is Aerovate Therapeutics’s market cap?
Currently, no data Available
When is Aerovate Therapeutics’s upcoming earnings report date?
Aerovate Therapeutics’s upcoming earnings report date is Nov 11, 2024 which is in 65 days.
How were Aerovate Therapeutics’s earnings last quarter?
Aerovate Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.038.
Is Aerovate Therapeutics overvalued?
According to Wall Street analysts Aerovate Therapeutics’s price is currently Undervalued.
Does Aerovate Therapeutics pay dividends?
Aerovate Therapeutics does not currently pay dividends.
What is Aerovate Therapeutics’s EPS estimate?
Aerovate Therapeutics’s EPS estimate is -$0.58.
How many shares outstanding does Aerovate Therapeutics have?
Aerovate Therapeutics has 28,867,710 shares outstanding.
What happened to Aerovate Therapeutics’s price movement after its last earnings report?
Aerovate Therapeutics reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 1.775%.
Which hedge fund is a major shareholder of Aerovate Therapeutics?
Among the largest hedge funds holding Aerovate Therapeutics’s share is RA Capital Management. It holds Aerovate Therapeutics’s shares valued at 15M.
---
Aerovate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.25 (18.42% Upside)
$2.25 (18.42% Upside)
Hedge Fund Trend
Increased
By 290.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.33%
12-Months-Change
Fundamentals
Return on Equity
-74.42%
Trailing 12-Months
Asset Growth
-28.29%
Trailing 12-Months
Company Description
Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
---
AVTE Stock 12 Month Forecast
Average Price Target
$2.25
▲(18.42% Upside)
Technical Analysis
Best Analysts Covering AVTE
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-90.35%
reiterated a buy rating 3 months ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -90.35% per trade.
---